
Chapman CR, Eckman J, and Bateman-House AS. Oversight of right-to-try and expanded access requests for off-trial access to investigational drugs. *Ethics & Human Research*. 2020. DOI. [Opens in a new tab](https://doi.org/)

Folkers KM, Leone S, and Caplan A. Patient advocacy organizations’ information for patients on pre-approval access to investigational treatments. *BMC Res Notes*. 2019. DOI. [Opens in a new tab](https://doi.org/)


Salgado R ... Massard C. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. *Eur J Cancer*. 2019. DOI. [Opens in a new tab](https://doi.org/)

Borysowski J ... Górski A. Expanded access: Growing importance to public health. *J Epidemiol Community Health*. 2018. DOI. [Opens in a new tab](https://doi.org/)

Caplan AL ... Gardner SL. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials. *J Med Ethics*. 2018. DOI. [Opens in a new tab](https://doi.org/)


Puthumana J ... Ross JS. Availability of investigational medicines through the U.S. Food and Drug Administration’s expanded access and compassionate use programs. *JAMA Network Open*. 2018. DOI. [Opens in a new tab](https://doi.org/)

Vox F ... Caplan AL. Medical crowdfunding for scientifically unsupported or potentially dangerous treatments. *JAMA*. 2018. DOI. [Opens in a new tab](https://doi.org/)


Moch KI. Ethical crossroads: Expanded access, patient advocacy, and the #SaveJosh social media campaign. *Med Access @ Point Care*. 2017. DOI. Opens in a new tab.
